Advertisement

Researchers have words of praise and warning for Covidien subsidiary eV3's Pipeline cerebral aneurysm device after several patients suffer from fatal brain bleeds post-treatment.

eV3's Pipeline embolization device

Researchers offered mixed messages on the safety and effectiveness of Covidien (NYSE:COV) subsidiary ev3 Inc.'s Pipeline embolization device, lauding the system as an option for patients with aneurysms that may not otherwise be treatable but warning of a significant risk of serious complications.

Researchers conducting post-market research on the PED reported "promising results" for the treatment, which diverts blood away from a brain aneurysm and promotes vessel tissue growth that blocks off the aneurysm over time, rather than providing immediate occlusion.

Advertisement
Advertisement